Discriminative stimulus properties of the selective and highly potent α2-adrenoceptor agonist, S18616, in rats: Mediation by the α2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin

Neuropharmacology

Volumn 51, Issue 4, 2006, Pages 718-726

  Dekeyne, Anne ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

2 adrenoceptors; Adrenergic; Antidepressant; Drug discrimination; S18616

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 2 (2 CHLORO 5 TRIFLUOROMETHYLPHENYLIMINO)IMIDAZOLIDINE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 2,3,9,13B TETRAHYDRO 1,2 DIMETHYL 1H IMIDAZO[3,4 F]MORPHANTHRIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ATIPAMEZOLE; BRIMONIDINE; CLONIDINE; IDAZOXAN; IMIDAZOLINE DERIVATIVE; MIANSERIN; MIRTAZAPINE; S 18616; SPIROIMIDAZOLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; MALE; MOLECULAR RECOGNITION; MOOD; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; SEXUAL FUNCTION; SUBSTITUTION REACTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MIANSERIN; OXAZOLES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 33748629392     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.05.012     Document Type: Article

References (53)

1. Arnt J. Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats. Behav. Pharmacol. 3 (1992) 11-18
2. Benelli A., Frigeri C., Bertolini A., and Genedani S. Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology 171 (2004) 250-258
3. Benkert O., Szegedi A., Philipp M., Kohnen R., Heinrich C., Heukels A., Van Der Vegte-Sende M., Baker R.A., Simmons J.H., and Schutte A.J. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J. Clin. Psychopharmacol. 26 (2006) 75-78
4. Bennett D.A., and Lal H. Discriminative stimuli produced by clonidine: an investigation of the possible relationship to adrenoceptor stimulation and hypotension. J. Pharmacol. Exp. Ther. 223 (1982) 642-648
5. Buccafusco J.J. Neuropharmacology and behavioral actions of clonidine, interactions with central neurotransmitters. Int. Rev. Neurobiol. 33 (1992) 55-107
6. Colpaert F.C., and Janssen P.A. Discriminative stimulus properties of xylazine in rat: discriminability and effects of putative alpha-2 adrenoceptor agonists and antagonists. J. Pharmacol. Exp. Ther. 235 (1985) 521-527
7. 2-agonists in neurosurgery. J. Clin. Neurosci. 12 (2005) 375-378
8. Crissman A.M., and O'Donnell J.M. Effects of antidepressants in rats trained to discriminate centrally administered isoproterenol. J. Pharmacol. Exp. Ther. 302 (2002) 606-611
9. 1 adrenergic receptors. Psychopharmacology 154 (2001) 70-75
10. Cunningham K.A., Callahan P.M., Craigmyle N.A., and Appel J.B. Discriminative stimulus properties of clonidine: substitution by ergot derivatives. Eur. J. Pharmacol. 119 (1985) 225-229
11. 2C receptor agonist, Ro 60-0175: a pharmacological analysis. Neuropharmacology 38 (1999) 415-423
12. Dekeyne A., and Millan M.J. Discriminative stimulus properties of antidepressant agents: a review. Behav. Pharmacol. 14 (2003) 391-407
13. Dykstra L.A., Preston K.L., and Bigelow G.E. Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology 130 (1997) 14-27
14. 2-adrenergic agonists for regional anesthesia - a clinical review of clonidine (1984-1995). Anesthesiology 85 (1996) 655-674
15. Gelenberg A.J., McGahuey C., Laukes C., Okayli G., Moreno F., Zentner L., and Delgado P. Mirtazapine substitution in SSRI-induced sexual dysfunction. J. Clin. Psychiatry 61 (2000) 356-360
16. 2-adrenoceptors. Eur. Neuropsychopharmacol. 12 Suppl. 3 (2002) S248
17. Goudie A.J., Smith J.A., and Millan M.J. Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology 171 (2004) 212-222
18. Goudie A.J., Smith J.A., Taylor A., Taylor M.A.I., and Tricklebank M.D. Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav. Pharmacol. 9 (1998) 699-710
19. Hall J.E., Uhrich T.D., Barney J.A., Arain S.R., and Ebert T.J. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth. Analg. 90 (2000) 699-705
20. Hayashi Y., and Maze M. α2-adrenoceptor agonists and anaesthesia. Br. J. Anaesth. 71 (1993) 108-118
21. Hieble J.P., Bondinell W.E., and Ruffolo R.R. α- and β-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J. Med. Chem. 38 (1995) 3416-3442
22. 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog. Neuro-psychopharmacol. Biol. Psychiatry 28 (2004) 819-827
23. Jordan S., Jackson H.C., Nutt D.J., and Handley S.L. Central α-2 adrenoceptors are responsible for a clonidine-induced cue in a rat drug discrimination paradigm. Psychopharmacology 110 (1993) 209-212
24. 2 site ligand, 2-BFI. J. Psychopharmacol. 10 (1996) 273-278
25. 2-adrenergic receptors. J. Pharmacol. Exp. Ther. 293 (2000) 1-7
26. Kujawa K., Leurgans S., Raman R., Blasucci L., and Goetz C.G. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch. Neurol. 57 (2000) 1461-1463
27. Lal H., and Yaden S. Discriminative stimulus produced by clonidine in spontaneously hypertensive rats: generalization to antihypertensive drugs with different mechanisms of actions. J. Pharmacol. Exp. Ther. 232 (1985) 33-39
28. 2-site ligand 2-BFI. Pharmacol. Biochem. Behav. 75 (2003) 427-433
29. Mateo Y., and Meana J.J. Determination of somatodendritic alpha2-adrenoceptor subtype located in the rat locus coeruleus that modulates cortical noradrenaline release in vivo. Eur. J. Pharm. 379 (1999) 53-57
30. Millan M.J. Descending control of pain. Prog. Neurobiol. 66 (2002) 355-474
31. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70 (2003) 83-244
32. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110 (2006) 1-236
33. 2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline. J. Pharmacol. Exp. Ther. 270 (1994) 958-972
34. 2-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J. Pharmacol. Exp. Ther. 292 (2000) 54-66
35. 2-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 295 (2000) 1192-1205
36. 2C receptors: a comparison with citalopram. Eur. J. Neuroscience 12 (2000) 1079-1095
37. Millan M.J., Lejeune F., and Gobert A. Reciprocal autoreceptor and heteroceptor control of serotonergic, dopaminergic and adrenergic transmission in frontal cortex: a review, and relevance to the actions of antidepressant agents. J. Psychopharmacol. 14 (2000) 114-138
38. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 295 (2000) 1206-1222
39. 3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 35 (2000) 79-95
40. 3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J. Pharmacol. Exp. Ther. 264 (1993) 1187-1197
41. Moens Y., Lanz F., Doherr M.G., and Schatzmann U. A comparison of the antinociceptive effects of xylazine, detomidine and romifidine on experimental pain in horses. Vet. Anaesth. Analg. 30 (2003) 183-190
42. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?. J. Psychopharmacol. 8 (1994) 193-195
43. 2-Adrenoceptors and depression. J. Psychopharmacol. 10 (1996) 35-42
44. 2 adrenergic subtypes. J. Pharmacol. Exp. Ther. 270 (1994) 946-957
45. Sanchez C., and Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19 (1999) 467-489
46. 2-adrenoceptor antagonist idazoxan. Psychopharmacology 99 (1989) 117-121
47. Schechter M.D. Discriminative stimulus effect of phenylephrine. Arch. Int. Pharmacodyn. Ther. 309 (1991) 20-31
48. 2A-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21 (2001) 4875-4882
49. 2-adrenoceptor agonist, after acute and persistent pain states. J. Pain 3 (2002) 234-243
50. Svensson T.H. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1145-1158
51. Szegedi A., and Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin. Pharmacother. 6 (2005) 631-641
52. Winter J.C., and Rabin R.A. Antagonism of the stimulus effects of yohimbine and 8-hydroxydipropylaminotetralin. Pharmacol. Biochem. Behav. 44 (1993) 851-855
53. 2B-adrenoceptor subtypes. Eur. J. Pharmacol. 168 (1989) 381-386